AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO

Rhea-AI Summary

Amgen (NASDAQ: AMGN) has announced a $900 million expansion of its Ohio manufacturing facility, which will create 350 new jobs, bringing the total employment to 750 positions and total investment in Central Ohio to over $1.4 billion.

The expansion builds upon Amgen's initial entry into Ohio in June 2021, when it established a state-of-the-art biomanufacturing facility that created 400 jobs. This investment is part of Amgen's broader U.S. manufacturing strategy, which includes nearly $5 billion in direct capital expenditures since 2017, generating approximately $12 billion in additional downstream output to the U.S. economy.

The Ohio expansion enhances Amgen's global biomanufacturing network and follows the company's recent announcement of a $1 billion investment for a second manufacturing plant in Holly Springs, NC.

Positive

• Major expansion with $900 million investment in Ohio manufacturing
• Creation of 350 new jobs, increasing total employment to 750
• $5 billion in U.S. capital expenditures generating $12 billion in downstream economic output
• Additional $1 billion investment in new North Carolina manufacturing plant

Negative

• None.

Insights

Financial Analyst

Amgen's $900M Ohio expansion demonstrates commitment to U.S. manufacturing, signaling confidence in future biologics demand.

Amgen's $900 million Ohio manufacturing expansion represents a significant capital allocation decision, bringing their total investment in the state to over $1.4 billion. This follows their recently announced $1 billion investment for a second plant in North Carolina, highlighting an aggressive U.S. manufacturing strategy.

The company has invested almost $5 billion in U.S. capital expenditures since the 2017 Tax Cuts and Jobs Act, generating approximately $12 billion in additional downstream economic output. This suggests favorable tax treatment may be influencing their U.S. investment strategy.

Creating 350 new jobs (750 total) in Ohio indicates substantial operational scale. While job creation is positive, the real value lies in the advanced manufacturing capabilities being established. CEO Robert Bradway's statement about ensuring "patients around the world have access to our innovative medicines" signals confidence in product pipeline and anticipated demand.

These investments position Amgen to enhance vertical integration and manufacturing control, potentially improving margins long-term while building supply chain resilience. The geographic diversification across multiple U.S. locations (Ohio and North Carolina) provides operational redundancy while maintaining the benefits of domestic production.

Manufacturing Industry Expert

Amgen's biomanufacturing expansion demonstrates strategic commitment to cutting-edge U.S. production capacity to support future growth.

Amgen's manufacturing expansion in Ohio represents a strategic strengthening of their biologics production network. The investment in "cutting-edge biologics manufacturing capabilities" suggests implementation of advanced production technologies that typically offer improved efficiency, quality control, and production flexibility.

The company's expansion history in Ohio is notable - starting with initial entry in 2021 and now significantly expanding that footprint. This phased approach indicates successful initial operations and strategic confidence in the location. Ohio's "supportive business climate, skilled workforce, and strategic location" highlights the critical factors driving site selection for complex biomanufacturing operations.

This expansion enhances Amgen's global manufacturing network while leveraging their "decades of operational expertise and technological advancements." Building sophisticated biologics manufacturing capacity requires substantial lead time, indicating this investment aligns with long-term product strategy and anticipated market demand.

The decision to expand existing sites rather than establishing entirely new locations typically accelerates time-to-operation while capitalizing on existing infrastructure, workforce, and operational knowledge. This dual-location strategy between Ohio and North Carolina creates manufacturing redundancy while maintaining the advantages of U.S. production.

Total Investment in the State to Exceed $1.4 Billion, 750 U.S. Jobs

THOUSAND OAKS, Calif., April 25, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its Ohio manufacturing facility, bringing the total number of jobs created to 750 and the total investment in Central Ohio to over $1.4 billion.

"Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988. Today's investment reinforces our ongoing commitment to expanding U.S. manufacturing and ensuring patients around the world have access to our innovative medicines," said Robert A. Bradway, chairman and chief executive officer at Amgen. "Ohio offers a supportive business climate, skilled workforce, and strategic location, making it an ideal choice for this next phase of our investment." 

Amgen first entered Ohio in June 2021, when it announced plans to invest in a state-of-the-art biomanufacturing facility in Central Ohio. This investment marked the company's expansion into the Columbus Region, which enhanced its U.S.-based manufacturing capabilities and created 400 jobs upon the facility's opening.  

"Ohio has built a strong foundation for economic development, which has led companies like Amgen to see Ohio as a premier destination for growth," said Ohio Governor Mike DeWine. "We are happy to see Amgen deepen its commitment to our state and look forward to the innovation and economic impact it will drive."

Since passage of the Tax Cuts and Jobs Act of 2017, Amgen has invested almost $5 billion in direct capital expenditures in the United States, generating an additional downstream output to the U.S. economy of approximately $12 billion.

The Ohio expansion enhances the company's global biomanufacturing network, leveraging decades of operational expertise and technological advancements and follows the company's recent announcement that it would invest $1 billion to build a second manufacturing plant in Holly Springs, NC. With these investments across the U.S., Amgen is focused on building the most cutting-edge biologics manufacturing capabilities in the world.

About Amgen 

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average^®, and it is also part of the Nasdaq-100 Index^®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram,  YouTube and Threads. 

Amgen Forward-Looking Statements

This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla^® (apremilast), our acquisitions of ChemoCentryx, Inc. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors) 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-announces-900-million-manufacturing-expansion-creation-of-350-new-jobs-in-ohio-302438570.html

SOURCE Amgen

FAQ

How many jobs will Amgen's new Ohio manufacturing expansion create?

Amgen's Ohio expansion will create 350 new jobs, bringing the total employment at the facility to 750 positions.

What is the total investment value of AMGN's Ohio manufacturing facility?

Amgen's total investment in Central Ohio will exceed $1.4 billion, including the new $900 million expansion.

When did Amgen first establish operations in Ohio?

Amgen first entered Ohio in June 2021 with the announcement of its initial biomanufacturing facility.

How much has AMGN invested in U.S. capital expenditures since 2017?

Since 2017, Amgen has invested almost $5 billion in direct capital expenditures in the United States, generating approximately $12 billion in downstream economic output.